Analysts Offer Predictions for Cresco Labs Q3 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Research analysts at Alliance Global Partners upped their Q3 2025 earnings per share (EPS) estimates for shares of Cresco Labs in a note issued to investors on Wednesday, March 12th. Alliance Global Partners analyst A. Grey now forecasts that the company will post earnings per share of ($0.02) for the quarter, up from their prior forecast of ($0.03). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Alliance Global Partners also issued estimates for Cresco Labs’ Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.09) EPS and FY2026 earnings at ($0.08) EPS.

Cresco Labs (OTCMKTS:CRLBF) last issued its quarterly earnings results on Friday, March 14th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The business had revenue of $176.00 million for the quarter, compared to analysts’ expectations of $172.10 million.

Several other brokerages also recently weighed in on CRLBF. Cormark raised Cresco Labs from a “hold” rating to a “moderate buy” rating in a research note on Monday. Atb Cap Markets lowered shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Cresco Labs presently has an average rating of “Buy” and a consensus target price of $3.00.

Cresco Labs Trading Down 4.0 %

Cresco Labs stock opened at $0.71 on Monday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The firm’s 50-day moving average is $0.88 and its 200-day moving average is $1.19. Cresco Labs has a 1 year low of $0.70 and a 1 year high of $2.60. The company has a market cap of $344.14 million, a P/E ratio of -3.53 and a beta of 1.79.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.